What Does Retatrutide Do? How the Triple Agonist Works
Retatrutide is a next-generation injectable peptide developed by Eli Lilly that simultaneously activates three separate metabolic receptors — GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide) and GCG (Glucagon). This triple mechanism is what makes retatrutide the most potent weight loss compound in clinical development, producing up to 24.2% body weight reduction in Phase 2 trials — more than any GLP-1 drug ever tested.
But what exactly does retatrutide do inside the body? This guide breaks down the science, the clinical evidence and what to realistically expect.
The Triple Mechanism — What Retatrutide Actually Does
1. GLP-1 Receptor Activation (the Ozempic® effect)
Like semaglutide (Ozempic®) and tirzepatide (Mounjaro®), retatrutide activates GLP-1 receptors. This produces the well-documented effects that made Ozempic® famous:
- Suppresses appetite by signalling satiety to the brain’s hunger centres
- Slows gastric emptying — food sits in the stomach longer, extending feelings of fullness
- Stimulates glucose-dependent insulin secretion — lowers blood sugar without hypoglycaemia risk
- Reduces glucagon secretion — prevents the liver from releasing excess glucose
2. GIP Receptor Activation (the Mounjaro® extra effect)
Retatrutide also activates GIP receptors — the same dual mechanism that makes tirzepatide (Mounjaro®) stronger than semaglutide:
- Enhances GLP-1 effects by amplifying the appetite suppression signal
- Directly affects fat cells (adipocytes) — promotes fat oxidation and reduces fat storage
- Improves insulin sensitivity in peripheral tissues
- May reduce GLP-1 side effects by modulating the GI response
3. Glucagon (GCG) Receptor Activation (the retatrutide difference)
This is what sets retatrutide apart from every other GLP-1 drug. By also activating glucagon receptors, retatrutide does something no other approved or compounded weight loss compound does:
- Increases resting energy expenditure (REE) — your body burns more calories at rest
- Promotes direct fat oxidation — the liver is signalled to burn fat stores for fuel
- Accelerates metabolic rate — total daily energy expenditure is elevated
- Works synergistically with GIP to create a combined fat-burning effect that neither receptor produces alone
The glucagon component is why retatrutide produces meaningfully greater weight loss than tirzepatide despite both having GLP-1 and GIP activity — the addition of GCG agonism adds a third fat-burning pathway.
What Does Retatrutide Do for Weight Loss? — Clinical Trial Data
The Phase 2 clinical trial published in the New England Journal of Medicine (2023) enrolled 338 adults with obesity or overweight. At 48 weeks at the 24mg dose:
- Average weight loss: 24.2% of total body weight
- Participants losing ≥20%: 83%
- Participants losing ≥25%: 57%
- Waist circumference reduction: Average 25.7cm
- Systolic blood pressure reduction: Average 8.5 mmHg
For context — a person weighing 100kg could expect to lose approximately 24kg on retatrutide over 48 weeks. At lower maintenance doses (8mg and 12mg), average weight loss was 17.5% and 22.8% respectively.
How Retatrutide Compares to Other GLP-1 Peptides
| Compound | Mechanism | Average Weight Loss | Trial Duration |
|---|---|---|---|
| Retatrutide 24mg | GLP-1 + GIP + GCG | 24.2% | 48 weeks |
| Tirzepatide 15mg (Mounjaro®) | GLP-1 + GIP | 22.5% | 72 weeks |
| Semaglutide 2.4mg (Wegovy®) | GLP-1 only | 14.9% | 68 weeks |
| Liraglutide 3mg (Saxenda®) | GLP-1 only | 8.0% | 56 weeks |
What Does Retatrutide Do Beyond Weight Loss?
Weight loss is the headline — but retatrutide produces significant metabolic improvements across multiple biomarkers:
- Blood glucose: Substantial reductions in fasting glucose and HbA1c — relevant for pre-diabetic and T2D patients
- Blood pressure: Average systolic BP reduction of 8.5 mmHg at 24mg
- Triglycerides: Significant reductions in fasting triglycerides
- Liver fat: Retatrutide dramatically reduces hepatic fat content — potentially useful for NAFLD/MAFLD
- Cardiovascular risk markers: Improvements in multiple CVD risk factors consistent with other GLP-1 agents
What Does Retatrutide Feel Like? What to Expect Week by Week
Weeks 1–4 (2mg starting dose)
Most users report subtle appetite changes — meals feel satisfying with less food. Minimal side effects at this dose. Weight loss of 0.5–1kg in the first month is typical.
Weeks 5–12 (4mg–8mg)
Appetite suppression becomes more pronounced. Spontaneous calorie reduction of 30–50% is common without intentional dieting. Weight loss accelerates — typically 1–2kg per month at this stage.
Weeks 13–24 (12mg–24mg)
Maximum efficacy phase. Significant appetite suppression. Many users report thinking about food completely differently — reduced food noise, fewer cravings. Weight loss of 1.5–3kg per month at maintenance doses.
Is Retatrutide Available in the UK?
Retatrutide is not yet MHRA approved for clinical prescription — it is currently in Phase 3 trials. However, it is available in the UK as a compounded research peptide from licensed suppliers. At UK Peptides Store, we stock Synedica Retatrutide 40mg and Alluvi Retatrutide 40mg/20mg pens — independently COA verified, physician-supervised, from £299/month with 48hr UK delivery.
Ready to start? Read our complete retatrutide dosage guide or WhatsApp us for a free protocol recommendation.
